Clinical Trials in Burnaby, Canada
1 recruiting
Showing 1–10 of 10 trials
Recruiting
Phase 3
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Metastatic Castration-resistant Prostate Cancer
Telix Pharmaceuticals (Innovations) Pty Limited520 enrolled31 locationsNCT06520345
Recruiting
Not Applicable
Postural Sway and Counterpressure Maneuvers for Pediatric Syncope
Postural Orthostatic tachycardia SyndromeOrthostatic intoleranceSyncope, Vasovagal
Simon Fraser University30 enrolled1 locationNCT05633693
Recruiting
Not Applicable
The Effect of Water Carbonation on Orthostatic Tolerance
Orthostatic HypotensionSyncopeVasovagal Syncope
Simon Fraser University25 enrolled1 locationNCT05621460
Recruiting
Phase 2
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Prostatic Cancer, Castration-Resistant
Novartis Pharmaceuticals130 enrolled50 locationsNCT07047118
Recruiting
Phase 4
ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS
Relapsing-remitting Multiple Sclerosis (RRMS)
Novartis Pharmaceuticals224 enrolled14 locationsNCT06733922
Recruiting
Phase 3
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Multiple Sclerosis
Sanofi900 enrolled338 locationsNCT06141486
Recruiting
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
Neuromyelitis Optica Spectrum DisorderNMOSDAQP4+ NMOSD
Alexion Pharmaceuticals, Inc.122 enrolled33 locationsNCT05966467
Recruiting
Phase 3
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
Acute Coronary Syndrome
DalCor Pharmaceuticals2,000 enrolled223 locationsNCT05918861
Recruiting
Not Applicable
Impact of Blood Phobia on Fainting Susceptibility
Syncope, VasovagalBlood, Injection, Injury Type Phobia
Simon Fraser University20 enrolled1 locationNCT06336031
Recruiting
Phase 2
Efficacy of QBKPN Site-Specific Immunomodulator in Improving Innate Immune Function & Reducing Respiratory Tract Infection in Older Adults
Immune Deficiency
Qu Biologics Inc.72 enrolled1 locationNCT05421325